REPLY: Siemens and Roboverse Reply Automate Inspection Processes With Mobile Robots
Roboverse Reply, the expert in robotics integration scenarios, has developed an end-to-end solution for AI-driven inspection processes in industrial environments together with Siemens, a leading technology company. Leveraging Siemens' "COMOS Mobile Worker", – an app used by organisations to plan and execute service technicians’ missions – technicians can now automate complex industrial maintenance tasks using autonomous mobile robots (AMRs) and drones from various manufacturers. This new function, that can be activated on request during software set up, enables users to significantly increase the life and operational reliability of their equipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212221939/en/
Thanks to the integration of the Roboverse Reply Platform, the ‘COMOS Mobile Worker’ app from Siemens now also allows robots and drones from different manufacturers to be scheduled for autonomous inspection and maintenance tasks. (Photo: Business Wire)
This is made possible thanks to the seamless integration of the Roboverse Reply Platform into the "COMOS Mobile Worker". The platform centrally orchestrates and fully automates the control of robots and drones during maintenance and inspection operations. By using advanced technologies such as Artificial Intelligence (AI) to detect anomalies, critical issues can be identified early, with all relevant information communicated to operators in real-time. When needed, augmented reality capabilities and precise navigation allow operators to manually intervene and take control. This high level of automation enables companies to identify and correct faults earlier, avoiding costly downtime.
Traditionally, controlling autonomous mobile robots has required specialised software and skilled personnel to operate, maintain and adapt as needed. The lack of such specialists, combined with high financial costs, has made deploying mobile robots challenging for most companies. But the Roboverse Reply Platform changes this landscape. Its seamless integration into Siemens’ familiar "COMOS Mobile Worker" environment allows existing employees to benefit from robotic support right from the start, without the need for lengthy additional training.
"With the robotic solution jointly developed by Siemens and Roboverse Reply, users can make their systems more efficient, more reliable and safer. This will increase their competitiveness in the long term," said Guido Schimmang, Product Manager, Siemens AG.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Roboverse Reply
Roboverse Reply specializes in the integration scenarios around Robotics and Reality Capture with Mixed Reality, where Cloud or On-Premises Infrastructures require Enterprise-Ready solutions. Roboverse Reply solutions include AI Skills with sensor-based anomaly detection, Fleet Management for Internet of Robotic Things, Digital Twins and Business Logic to deliver end-to-end support for the customers. The Roboverse Reply platform enables Autonomous Preventive Inspection to prolong the lifespan of your infrastructures and interactive telepresence, crucial for Safety and Security purposes. www.roboverse.reply.com
Siemens
Siemens AG (Berlin and Munich) is a leading technology company focusing on industry, infrastructure, mobility and healthcare. The company's mission is to develop technologies that improve everyday life for everyone. By connecting the real world with the digital world, it enables customers to accelerate their digital and sustainable transformation. This makes factories more efficient, cities more livable and transport more sustainable. Siemens is the majority owner of the publicly traded Siemens Healthineers, a global leader in medical technology that is transforming healthcare. For everyone. Everywhere. Sustainably. In fiscal 2024, which ended on 30 September 2024, the Siemens Group had revenue of €75.9 billion and profit after tax of €9.0 billion. As of 30 September 2024, the company had approximately 312,000 employees worldwide on a continuing basis. www.siemens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212221939/en/
Contacts
Press contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +390117711594
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press Release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom